Last reviewed · How we verify
ParaGard® TCu380A
ParaGard TCu380A is a copper-releasing intrauterine device that prevents pregnancy through copper ion toxicity to sperm and alteration of the uterine environment.
ParaGard TCu380A is a copper-releasing intrauterine device that prevents pregnancy through copper ion toxicity to sperm and alteration of the uterine environment. Used for Contraception in women of reproductive age.
At a glance
| Generic name | ParaGard® TCu380A |
|---|---|
| Also known as | T380 |
| Sponsor | FHI 360 |
| Drug class | Intrauterine contraceptive device (copper-based) |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | Phase 3 |
Mechanism of action
The device releases copper ions that are toxic to sperm, impairing their motility and fertilization capacity. Additionally, the copper and inflammatory response triggered by the device alter the endometrial environment, making implantation of a fertilized egg unlikely. This multi-mechanism approach provides long-acting reversible contraception without systemic hormonal effects.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Increased menstrual bleeding
- Menstrual cramping
- Pelvic pain
- Device expulsion
- Uterine perforation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ParaGard® TCu380A CI brief — competitive landscape report
- ParaGard® TCu380A updates RSS · CI watch RSS
- FHI 360 portfolio CI